Meeting Banner
Abstract #0577

Integration of DCE-MRI and Molecular Markers for Improved Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy

Alina Tudorica1, Karen Oh1, Yiyi Chen1, Neda Jafarian1, Arpana Naik1, Kathleen Kemmer1, Megan Troxell1, Eric Goranson1, Aneela Afzal1, May Mishal1, and Wei Huang1

1Oregon Health & Science University, Portland, OR, United States

The goal is to determine if integration of DCE-MRI and molecular markers improves early prediction of breast cancer response to neoadjuvant chemotherapy (NACT). 49 patients undergoing standard of care NACT had DCE-MRI before and after the first NACT cycle, with 12 of them achieving pathologic complete response (pCR) after NACT. Pharmacokinetic (PK) analysis of DCE-MRI data was performed using the shutter-speed model. Changes in PK parameters were superior to changes in tumor size for early prediction of pCR. The improvement in predictive performance by combining DCE and HR, HER2 molecular markers was statistically significant compared to using MRI markers alone.

This abstract and the presentation materials are available to members only; a login is required.

Join Here